Latest Expert Exchange Queries
sitemapHome | Registration | Job Portal for CA's | Expert Exchange | Currency Converter | Post Matrimonial Ads | Post Property Ads
 
 
News shortcuts: From the Courts | News Headlines | VAT (Value Added Tax) | Service Tax | Sales Tax | Placements & Empanelment | Various Acts & Rules | Latest Circulars | New Forms | Forex | Auditing | Direct Tax | Customs and Excise | ICAI | Corporate Law | Markets | Students | General | Indirect Tax | Mergers and Acquisitions | Continuing Prof. Edu. | Budget Extravaganza | Transfer Pricing
 
 
 
 
Popular Search: due date for vat payment :: TAX RATES - GOODS TAXABLE @ 4% :: list of goods taxed at 4% :: form 3cd :: VAT RATES :: ICAI offer Get Windows 7,Office 2010 in Rs.799 Taxes :: ACCOUNTING STANDARD :: ACCOUNTING STANDARDS :: empanelment :: articles on VAT and GST in India :: cpt :: TDS :: ARTICLES ON INPUT TAX CREDIT IN VAT :: VAT Audit :: Central Excise rule to resale the machines to a new company
 
 
« Mergers and Acquisitions »
 Preparing for International Mergers and Acquisitions
 Merger control regime: CCI sharing concerns at early stages would reduce trust deficit
  Deals of the day-Mergers and acquisitions
 Oil companies’ mergers: Indian Oil Corporation chairman B Ashok says ‘Worthwhile to look at the possibilities
 It's complicated: Regulatory hurdles that Vodafone-Idea merger could face
 China FX head Pan Gongsheng says overseas mergers and acquisitions like ‘a rose with thorns’
 Technology drove Michigan's mergers and acquisitions in 2016
  Pharmaceutical Mergers And Acquisitions – M&A In The Biopharmaceutical Industry And The Impact On Innovation
 Road ahead for Indian M&A seems brightly lit: PwC report
 Fed eases bank merger rules by lifting size threshold for review
 Deals of the day-Mergers and acquisitions

No tax impact on shareholders after Sun-Ranbaxy merger
April, 08th 2014

Shareholders of Ranbaxy are bound to be concerned about the tax implications, if any, arising on the share-swap in the Ranbaxy-Sun Pharma deal. Under the arrangement, Ranbaxy shareholders will receive 0.8 shares of Sun Pharma for each share of Ranbaxy. This exchange ratio represents an implied value of Rs 457 for each Ranbaxy share — a premium of 18% to Ranbaxy's 30-day volume-weighted average share price and a premium of 24.3% to Ranbaxy's 60-day volume-weighted average share price, computed as on the closing date of April 4.

Sun Pharma's official release adds, "The transaction is expected to represent a tax-free exchange to Ranbaxy shareholders who are expected to own 14% of the combined company."

No transfer under tax laws

The share-swap transaction, wherein for one share of Ranbaxy shareholders will get 0.8 shares of Sun Pharma, is not considered as a 'transfer' under tax laws and no capital gains will arise in the hands of the Ranbaxy shareholders.

Hold allotted Sun Pharma shares for 12 months

Long-term capital gains on sale of shares via a stock exchange are currently exempt from capital gains tax and only a nominal securities transaction tax is payable. However, to qualify as a long-term capital asset, the share must be held for twelve months.

"Tax laws, while defining long-term capital assets, also provide for beneficial treatment to shareholders covered under merger agreements in respect of their new shares, by including the period of shareholding of the original shares," explains Punit Shah, co-head (tax) at KPMG.

In other words the period of holding of the original Ranbaxy shares would also be considered. Thus, assuming that Mr. A had purchased 100 Ranbaxy shares in January 2012, he will now get 80 shares of Sun Pharma. If he sells the Sun Pharma shares soon after they are allotted to him, the sale will still be of a long-term capital asset (as the date for computing the period of holding will be from January 2012). Ranbaxy shareholders wishing to sell their Sun Pharma shares should ensure that the cumulative period of holding is at least twelve months, to avoid any capital gains tax. As of March 31, 2014, the general domestic public holding in Ranbaxy with nearly 533 lakh shares was approximately 13%.

 
 
Home | About Us | Terms and Conditions | Contact Us
Copyright 2017 CAinINDIA All Right Reserved.
Designed and Developed by Binarysoft Technologies Pvt. Ltd.
Content Management System development CMS development Content Management Solutions CMS Solutions Content Management Services CMS Services CMS Software

Transfer Pricing | International Taxation | Business Consulting | Corporate Compliance and Consulting | Assurance and Risk Advisory | Indirect Taxes | Direct Taxes | Transaction Advisory | Regular Compliance and Reporting | Tax Assessments | International Taxation Advisory | Capital Structuring | Withholding tax advisory | Expatriate Tax Reporting | Litigation | Badges | Club Badges | Seals | Military Insignias | Emblems | Family Crest | Software Development India | Software Development Company | SEO Company | Web Application Development | MLM Software | MLM Solutions